235 related articles for article (PubMed ID: 14673757)
1. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.
Lederman HM; Williams PL; Wu JW; Evans TG; Cohn SE; McCutchan JA; Koletar SL; Hafner R; Connick E; Valentine FT; McElrath MJ; Roberts NJ; Currier JS;
J Infect Dis; 2003 Dec; 188(12):1794-803. PubMed ID: 14673757
[TBL] [Abstract][Full Text] [Related]
2. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
3. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
5. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
Weinberg A; Gona P; Nachman SA; Defechereux P; Yogev R; Hughes W; Wara D; Spector SA; Read J; Elgie C; Cooper M; Dankner W;
J Infect Dis; 2006 Jan; 193(2):302-11. PubMed ID: 16362896
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
8. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
9. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
10. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
[TBL] [Abstract][Full Text] [Related]
11. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
13. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
14. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
17. Effect of IL-2 on hepatitis C virus RNA levels in patients co-infected with human immunodeficiency virus receiving HAART.
Tedaldi EM; Chen L; Markowitz N; Kelly L; Abrams D;
J Viral Hepat; 2005 Jul; 12(4):414-20. PubMed ID: 15985013
[TBL] [Abstract][Full Text] [Related]
18. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
19. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.
Kovacs A; Montepiedra G; Carey V; Pahwa S; Weinberg A; Frenkel L; Capparelli E; Mofenson L; Smith E; McIntosh K; Burchett SK;
J Infect Dis; 2005 Jul; 192(2):296-302. PubMed ID: 15962224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
